{"news_desk": "Business", "print_page": "1", "subsection_name": null, "section_name": "Business Day", "byline": {"original": "By KATIE THOMAS", "person": [{"firstname": "Katie", "rank": 1, "lastname": "THOMAS", "organization": "", "role": "reported"}]}, "abstract": null, "type_of_material": "News", "word_count": "1098", "keywords": [{"rank": "1", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Biogen Idec Inc", "is_major": "N", "name": "organizations"}, {"rank": "3", "value": "Spinal Muscular Atrophy", "is_major": "N", "name": "subject"}, {"rank": "4", "value": "Health Insurance and Managed Care", "is_major": "N", "name": "subject"}, {"rank": "6", "value": "Food and Drug Administration", "is_major": "N", "name": "organizations"}], "lead_paragraph": "Spinraza, a \u201clife-changing\u201d drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that.", "pub_date": "2016-12-31T00:40:18+0000", "document_type": "article", "source": "The New York Times", "snippet": "Spinraza, a \u201clife-changing\u201d drug for spinal muscular atrophy, will cost as much as $750,000 for the first year of treatment and $375,000 annually after that....", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wide": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbWide.jpg", "wideheight": "126"}, "type": "image", "width": 190, "url": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbWide.jpg"}, {"height": 398, "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "398", "xlarge": "images/2016/12/31/business/31DRUG1/31DRUG1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2016/12/31/business/31DRUG1/31DRUG1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "url": "images/2016/12/31/business/31DRUG1/31DRUG1-thumbStandard.jpg"}], "web_url": "http://www.nytimes.com/2016/12/30/business/spinraza-price.html", "slideshow_credits": null, "blog": [], "_id": "5866fe7a95d0e039260786c9", "headline": {"main": "Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval", "print_headline": "Hefty Price Set on a New Drug That Can Stunt  Muscle Disease"}}